Close Bookmark and Share This Page

Save to Browser Favorites / Bookmarks

Ask backflip blinklist BlogBookmark Bloglines BlogMarks Blogsvine BuddyMarks BUMPzee! CiteULike Connotea del.icio.us

Digg diigo DotNetKicks DropJack dzone Facebook Fark Faves Friendsite folkd.com Furl Google

Jamespot Jeqq Kaboodle kirtsy linkaGoGo LinkedIn Ma.gnolia Mister Wong Mixx MySpace Netvouz Newsvine

oneview OnlyWire PlugIM Propeller Reddit Segnalo Shoutwire Simpy Slashdot Surphace Sphinn Spurl

Squidoo StumbleUpon Technorati ThisNext Twitter Webride Windows Live Yahoo!

Email This to a Friend

  Link HTML: 

 Permalink: 

 If you like this then please subscribe to the RSS Feed.

Powered by Bookmarkify™

More »

XOMA

XOMA Limited (NASDAQ:XOMA) – Shares broke out on a bullish tear as XOMA announced their lead drug candidate XOMA 052 an antibody to interleukin-1 beta, an orphan drug for the treatment of Behcet’s disease, received FDA designation for Orphan Drug status. Shares reached an intraday high of $.395.

Regards,

Don